Ask Warren

JONBUR Research · Initiation

Kwangdong Pharmaceutical · 009290 · Biotech & Pharma

Kwangdong Pharmaceutical: Thin Margins, Low Book Multiple and a Wide Model Range

Why this report

Start of coverage: written when a reader opened this company and there was no report yet.

Kwangdong Pharmaceutical's revenue has grown every year in the data, but operating margin stays near 2% and returns on equity are low. The shares trade at 0.5x book value and 15.2x earnings, and a model estimate sits above the current price with a very wide bear-to-bull range.

Written Oct 21, 2026 · Data as of Oct 20, 2026 · 0 views

This is not financial advice. The report does not recommend buying or selling anything.

XfWATGr/in@

Thesis

The data supports a picture of a steadily growing but low-profit business. Revenue rose from ₩1.34T in 2021 to ₩1.66T in 2025, yet operating margin has slipped from 3.4% to 1.9% over the same period. The share price is 47.8% below its 52-week high of ₩12,800 but 29.7% above its low of ₩5,150, and it has risen 9.0% in one month, 13.6% in three months and 18.2% in one year.

The low price-to-book of 0.5x reflects a return on equity of only 3.6%. The data does not show a clear driver for a margin recovery. Recent news is about advertising and pricing controversy over a product, and the data gives no figures on its financial impact.

Business overview

Kwangdong Pharmaceutical is a KOSPI-listed company in the biotech and pharma sector, founded in 1963 and listed in 1989. It has 49,799,808 listed shares and a market capitalization of ₩332.7B. It has two co-CEOs, 최성원 and 박상영. Revenue has grown each year in the data: 7.0% in 2022, 5.8% in 2023, 8.3% in 2024 and 1.1% in 2025. Growth in 2025 was clearly slower than in prior years. The data does not break revenue down by product or segment.

Financial analysis

These figures come from filed financial statements. Trailing twelve-month revenue to H1 2026 was ₩1.71T, with operating income of ₩33.5B (2.0% margin) and net income of ₩21.8B (1.3% margin). Return on equity was 3.6%.

For 2025, revenue was ₩1.66T, operating income ₩31.0B and net income ₩21.0B. Net income in 2024 was ₩40.5B, nearly double 2025, with ROE of 7.2% versus 3.4%.

The balance sheet shows liabilities at 85.9% of equity, cash of ₩87.4B and borrowings of ₩303.9B, so borrowings are about 3.5 times cash. Trailing free cash flow was just ₩4.9B, which is small relative to profit and borrowings.

Valuation

The shares trade at 15.2x earnings, 0.5x book value and 0.2x sales, with a dividend yield of 1.5%. Enterprise value is ₩458.9B. EV/EBITDA is not available. Year-end P/E was 13.9x in 2025 and 6.7x in 2024, so the current multiple is above the 2024 level, partly because earnings fell. Year-end P/B has ranged from 0.4x to 0.7x over five years, so the current 0.5x is within its own history.

The listed biotech peers trade at much higher multiples: P/E from 14.6x to 83.3x and P/B from 2.6x to 30.0x. These are larger and differently positioned companies, so the comparison is only a rough reference.

The valuation model (5-year discounted cash flow at a 6.5% rate, based on trailing figures to H1 2026) gives a base-case estimate of ₩8,350 per share versus the ₩6,680 close. The bear case is ₩0 and the bull case ₩30,572. This is a model estimate based on the assumptions shown, not a target, and the very wide range shows how sensitive it is to thin margins and small cash flow.

Catalysts

  • The half-year report filed on 2026-08-14 showed trailing operating margin of 2.0%, and the next quarterly filing will show whether margins improve.
  • Filings on 2026-10-02 and 2026-10-12 (5%+ holding reports) and a change in the largest shareholder's holdings on 2026-08-28 point to ongoing shifts in ownership.
  • News on 2026-10-14 and 2026-10-21 covers criticism of advertising and pricing for the Chimhyang pills product, including a referral of sellers to police, which could affect brand perception.
  • Foreign ownership fell from 16.5% to 15.9% over 60 days, and the 20-day flows show foreign selling offset by retail buying, so changes in that pattern may matter.

Risks

  • Operating margin of about 2% leaves little buffer against cost increases or pricing pressure.
  • Revenue growth slowed to 1.1% in 2025 from 8.3% in 2024.
  • Borrowings of ₩303.9B are far larger than cash of ₩87.4B, and free cash flow was only ₩4.9B.
  • Regulatory and reputational issues over advertising and pricing of a product are visible in recent news, with no financial impact quantified.
  • The model range from ₩0 to ₩30,572 shows very high uncertainty in any cash-flow-based estimate.

Closing view

The data shows a long-established company with steadily growing sales but persistently thin profitability, modest returns and a leveraged balance sheet. A 0.5x book multiple and a base-case model estimate above the current price are set against low ROE, weak free cash flow and a very wide bear-to-bull range. Recent price gains and the news on advertising add uncertainty. Further filings on margins and cash flow will show whether profitability is improving.

Model estimate of fair value

Bear
₩0
-100%
Base
₩8,350
+29%
Bull
₩30,572
+374%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Base case of the 5-year discounted cash flow model on the stock's Valuation tab (statements TTM to H1 2026; discount rate 6.5%). Bear and Bull move the main assumptions by fixed steps. See and change the assumptions

Filings and data used

Report history

  1. Oct 21, 2026InitiationStart of coverage (reader request)Kwangdong Pharmaceutical: Thin Margins, Low Book Multiple and a Wide Model Range

Built only from jonbur's own data: prices and investor flows, filed financial statements and filings, and news headlines. Disclosed (filed) data is labelled as such. Written by AI and may contain mistakes.

This is not financial advice. The report does not recommend buying or selling anything.

Source: KRX statistical information